Effect of fluvoxamine on outcomes of nonhospitalized patients with COVID-19: A systematic review and meta-analysis
Li-Chin Lu, Chien-Ming Chao, Shen-Peng Chang, Shao-Huan Lan, Chih-Cheng Lai
Journal of Infection and Public Health, doi:10.1016/j.jiph.2022.10.010
Objectives: This meta-analysis investigated the use of fluvoxamine for the treatment of nonhospitalized patients with COVID-19. Methods: PubMed, Web of Science, Ovid medline, Embase, Scopus, Cochrane Library databases, and ClinicalTrials.gov were searched for studies published before June 25, 2022. Only clinical studies that compared the efficacy and safety of fluvoxamine with other alternatives or placebos in the treatment of nonhospitalized patients with COVID-19 were included. Results: Four studies with 1814 patients, of whom 912 received fluvoxamine, were included in this study. Compared with the control group receiving placebo or no therapy, the study group receiving fluvoxamine demonstrated a lower risk of hospitalization and emergency department (ED) visits (odds ratio [OR], 0.59; 95 % CI, 0.44-0.79; I 2 = 26 %). In addition, the rate of hospitalization remained significantly lower in patients who received fluvoxamine than in the control group (OR, 0.69; 95 % CI, 0.51-0.94; I 2 = 36 %). Although the study group demonstrated a lower risk of requirement of mechanical ventilation and intensive care unit admission, and mortality than the control group, these differences were nonsignificant. Finally, fluvoxamine use was associated with a similar risk of adverse events as that observed in the control group. Conclusion: Fluvoxamine can be safely used in nonhospitalized patients with COVID-19 and can reduce the hospitalization rate or ED visits in these patients.
Competing interests The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants, or patents received or pending, or royalties.
Ethical approval Not required.
Appendix A. Supporting information Supplementary data associated with this article can be found in the online version at doi:10.1016/j.jiph.2022.10.010.
Calusic, Marcec, Luksa, Jurkovis, Kovac et al., Safety and efficacy of fluvoxamine in COVID-19 ICU patients: an open label, prospective cohort trial with matched controls, Br J Clin Pharm
Chen, Nirula, Heller, Gootlieb, Boscia et al., SARS-CoV-2 neutralizing antibody LY-CoV555 in outpatients with Covid-19, N Engl J Med
Deeks, Casirivimab/Imdevimab: first approval, Drugs
Dougan, Nirula, Azizad, Mocherla, Gootlieb et al., Bamlanivimab plus etesevimab in mild or moderate Covid-19, N Engl J Med
Gandhi, Lynch, Rio, Mild or moderate Covid-19, N Engl J Med
Gottlieb, Nirula, Chen, Boscia, Heller et al., Effect of bamlanivimab as monotherapy or in combination with etesevimab on viral load in patients with mild to moderate COVID-19: a randomized clinical trial, JAMA
Guo, Harari, Chernecki, Thorlund, Forrest, Fluvoxamine for the early treatment of COVID-19: a meta-analysis of randomized clinical trials, Am J Trop Med Hyg
Gupta, Gonzalez-Rojas, Juarez, Casal, Moya et al., Early treatment for Covid-19 with SARS-CoV-2 neutralizing antibody sotrovimab, N Engl J Med
Hashimoto, Suzuki, Hashimoto, Mechanisms of action of fluvoxamine for COVID-19: a historical review, Mol Psychiatry
Hashimoto, Suzuki, Hashimoto, Old drug fluvoxamine, new hope for COVID-19, Eur Arch Psychiatry Clin Neurosci
Hoertel, Sánchez-Rico, Vernet, Beeker, Jannot et al., Association between antidepressant use and reduced risk of intubation or death in hospitalized patients with COVID-19: results from an observational study, Mol Psychiatry
Kornhuber, Hoertel, Gulbins, The acid sphingomyelinase/ceramide system in COVID-19, Mol Psychiatry
Lai, Liu, Wang, Wang, Hsueh et al., Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths, J Microbiol Immunol Infect
Lai, Shih, Ko, Tang, Hsueh, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges, Int J Antimicrob Agents
Lee, Vigod, Bortolussi-Courval, Hanula, Boulware et al., Fluvoxamine for outpatient management of COVID-19 to prevent hospitalization: a systematic review and meta-analysis, JAMA Netw Open
Lenze, Mattar, Zorumski, Stevens, Schweiger et al., Fluvoxamine vs placebo and clinical deterioration in outpatients with symptomatic COVID-19: a randomized clinical trial, JAMA
Mahase, Covid-19: Molnupiravir reduces risk of hospital admission or death by 50 % in patients at risk, MSD reports, BMJ
Moher, Liberati, Tetzlaff, Altman, Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement, BMJ
Mueller, Riederer, Müller, Neuropsychiatric drugs against COVID-19: What is the clinical evidence?, Pharmacopsychiatry
Reis, Santos Moreira-Silva, Silva, Thabane, Milagres et al., Effect of early treatment with fluvoxamine on risk of emergency care and hospitalisation among patients with COVID-19: the TOGETHER randomised, platform clinical trial, Lancet Glob Health
Seftel, Boulware, Prospective cohort of fluvoxamine for early treatment of coronavirus disease 19, Open Forum Infect Dis
Seo, Kim, Bae, Park, Chung et al., Fluvoxamine treatment of patients with symptomatic COVID-19 in a community treatment center: a preliminary result of randomized controlled trial, Infect Chemother
Sterne, Savović, Page, Elbers, Blencowe et al., RoB 2: a revised tool for assessing risk of bias in randomised trials, BMJ
Sukhatme, Reiersen, Vayttaden, Sukhatme, Fluvoxamine: a review of its mechanism of action and its role in COVID-19, Front Pharm